Results 201 to 210 of about 113,185 (266)

Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study. [PDF]

Hematol Transfus Cell Ther
Emiliano EG, Santos GEAA, Miranda ECM, Duarte GBO, Amarante GBD, De Souza CA, Pagnano KBB.   +6 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance? [PDF]

Hematol Transfus Cell Ther
Omar MM, Alanazi MA, Jackson DE.
europepmc   +1 more source

Splicing Factor Mutations in Clonal Hematopoiesis and Progression to Myeloid Neoplasms

Cancer Science, EarlyView.
Splicing factor (SF)‐mutant CH is characterized by relatively late emergence and accelerated clonal expansion in older individuals. This review summarizes its clonal dynamics, disease‐associated consequences of SF mutations in myeloid neoplasms, and candidate mechanisms that may contribute to age‐dependent selection.
Yang Lyu, Yutong Zhang, Ayana Kon
wiley   +1 more source

Case Report: Chronic myeloid leukemia in a 13-year-old-a rare pediatric case of extreme hyperleukocytosis in chronic phase. [PDF]

Front Med (Lausanne)
Asees M, Abdalhaq T, Amer J.
europepmc   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship. [PDF]

Biomedicines
Leyfman Y, Azeez AH, Dohadwala TK, Nadar S, Vaishnav R, Khan S, Rangrej VJ, Cortiana V, Park C.   +8 more
europepmc   +1 more source

Targeting m6A Modifications Regulating Ferroptosis Offers Novel Therapy in Diseases

Cell Proliferation, EarlyView.
m6A RNA modification regulates ferroptosis by balancing iron metabolism, lipid peroxidation, and antioxidant defenses. Dysregulated m6A signaling disrupts pro‐ and anti‐ferroptotic factors, leading to excess ROS, Fe3+ accumulation, and lipid peroxidation–driven cell death. Targeting m6A‐mediated ferroptotic regulation represents a promising therapeutic
Lida Du, Joshua S. Fleishman, Shuang Wu, Yuan Zhou, Clara X. Wang, Haitong Wang, Yumin Wang, Hongquan Wang   +7 more
wiley   +1 more source

Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells. [PDF]

Med Oncol
Çelik B, Kiraz Y, Şahin Y, Tezcanlı Kaymaz B.   +3 more
europepmc   +1 more source

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

British Journal of Haematology, EarlyView.
Jong Wook Lee, Kohei Hosokawa, Jun Ho Jang, Naoshi Obara, Masashi Sawa, Kensuke Usuki, Gaku Oshikawa, Masahiro Kizaki, Koji Nagafuji, Ting‐An Lin, Hitoshi Hanamoto, Yeung‐Chul Mun, Toshiro Kawakita, Kazunori Imada, June‐Won Cheong, Sung‐Soo Park, Takayuki Tabayashi, Masaru Gamou, Kenta Murotani, Hirohito Yamazaki   +19 more
wiley   +1 more source